Dublin, Ireland-headquartered Cosmo Pharmaceuticals has announced a new head of investor relations in Hazel Winchester, who will take up the position on January 10, 2022.
Described by the company as a ‘seasoned IR professional,’ Winchester brings to the role almost two decades of IR experience across various pharmaceuticals firms and IR roles. According to her LinkedIn profile, Winchester’s most recent position was as IR manager at Basilea Pharmaceutica in Basel, Switzerland.
Winchester previously worked with different companies in Toronto, Canada, including one which grew from small to large-cap listed on the TSX and NYSE, states Cosmo. She has served on the board of CIRI and recently joined the board of the IR Club Switzerland.
‘We have been looking for quite some time on how to fill this important role and we believe we have now found in Hazel the right person,’ says Alessandro Della Chà, CEO of Cosmo, in a statement welcoming Winchester to the firm. ‘I trust she will help us strengthen the relationship with investors at this very important moment in the history of Cosmo.’
The firm is a ‘specialized pharmaceuticals company,’ focused on gastrointestinal disorders and improving endoscopy quality measures. Its GI Genius is an artificial intelligence device designed to help detect potential signs of colon cancer.
Garnet Roach
An award-winning journalist, Garnet Roach joined IR Magazine in October 2012, working on both the editorial and research sides of the publication. Prior to entering the world of investor relations, her freelance career covered a broad range of...
